Últimas investigaciones científicas sobre cáncer colorrectal
Copia esta URL y pégala en tu lector RSS favorito (Feedly, Inoreader, etc.)
https://crcwarriors.org/api/scientific-news.php?action=rss
Colorectal cancer (CRC), a highly aggressive malignancy, continues to threaten many lives. Chimeric antigen receptor-natural killer cell (CAR-NK) therapy has emerged as a promising therapeutic approach for CRC. CD133 is an important marker in many solid tumors, especially CRC. In this study, we gene...
Due to their complex anatomy, high heterogeneity, and immunosuppressive tumour microenvironment, gastrointestinal cancers severely restrict the effective delivery and function of oncolytic viruses (OVs). This review summarises current multidimensional strategies to improve OV delivery efficiency. Fi...
Colorectal cancer (CRC) is the most common malignant tumor of the digestive system. Exploring effective diagnostic markers and therapeutic targets has great significance for the diagnosis and treatment of CRC. ARID1A is frequently mutated in CRC, but its prognostic value for this disease remains con...
The invasive front and peritumoral region of colorectal cancers are replete with powerful prognostic biomarkers that can predict oncologic outcomes with far greater precision than achievable by tumor, node, metastasis (TNM) stage alone. This article considers both established and emerging invasive f...
Increasing efforts have focused on identifying vulnerabilities within the signaling networks of KRAS that sustain its oncogenic activity. Recently, Furin-like enzymes or proprotein convertase, proteases responsible for the activation of various signaling molecules, have emerged as key regulators. Fu...
Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC) patients, but its clinical efficacy is hindered by therapeutic resistance. Here, we demonstrate that DNA ligase 1 (LIG1) is highly expressed in CRC and impairs chemosensitivity, highlighting LIG1 as a promising th...
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with chemotherapy resistance representing a critical barrier to effective treatment. The tumor microenvironment (TME) plays a pivotal role in mediating resistance through complex immunosuppressive mechanisms that remain inc...
Population-wide genomic screening (PWGS) programs can identify individuals at increased risk for Hereditary Breast and Ovarian Cancer (HBOC), Lynch Syndrome (LS), and Familial Hypercholesterolemia (FH). However, uptake of follow-up genetic counseling (GC) remains inconsistent, and limited data descr...
The costs of cancer therapies are rising rapidly worldwide, with novel therapies such as targeted treatment and immunotherapies being major contributors, but their effectiveness can be low or uncertain due to limited postmarket surveillance. Reliable biomarkers to identify patients highly unlikely t...
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Although substantial advances in chemotherapy, molecular targeted therapy, and immunotherapy have improved clinical outcomes in select patient populations, therapeutic resistance remains the major ob...
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-driven malignancy characterized by a profoundly immunosuppressive tumor microenvironment (TME) that severely limits the efficacy of immune checkpoint blockade (ICB). In the modern comprehensive treatment era, the 5‑year overall survival...
Colorectal cancer (CRC) remains a major cause of cancer-related mortality, and the widespread occurrence of drug resistance constitutes a central bottleneck that constrains therapeutic efficacy and adversely affects long-term patient outcomes. Current therapeutic strategies, guided by the Tumor-Node...
Antibody-drug conjugate (ADC) is a novel type of targeted systemic therapy that is changing the current landscape of tumor treatment. By integrating the specificity of antibodies with the cytotoxic effects of their payloads, ADCs facilitate precise tumor killing. In solid tumors such as breast cance...
Copper bioavailability has been identified as a potential target for KRAS-mutant colorectal cancer, a disease for which treatment options remain limited. Therefore, we investigated copper homeostasis in isogeneic colorectal cancer cell models carrying distinct KRAS codon 12 mutations (G12C, G12D and...
The immune checkpoint programmed ligand 1 (PD-L1) is expressed in various solid tumors and is associated with immunotherapy prognosis. Dynamic assessment of PDL1 expression levels helps identify patients who may benefit from immunotherapy. Atezolizumab is a monoclonal antibody that targets PD-L1 and...
Dysfunctional tumor vasculature limits immune checkpoint blockade efficacy. We have recently established that endothelial SPEN deficiency promotes tumor vessel normalization by suppressing RNA polymerase I (RNAPI)-mediated rDNA transcription via inducing disrupted ribosome biogenesis and nucleolar s...
The efficacy of chimeric antigen receptor T (CAR-T) cell therapy in solid tumors is limited by the scarcity of stable antigen targets. To enhance CAR-T cell immunotherapy for solid tumors, we developed an integrated system that simultaneously introduces a surface antigen target for CAR-T cells and r...
Ferroptosis is a regulated necrotic cell death pathway, which demonstrates significant anticancer potential. As the only ferroptosis-based nanomedicine under clinical trial evaluation, carbon nanoparticle-Fe (II) complex (CNSI-Fe) not only induces ferroptosis in tumor cells, but also serves as photo...
Over the decades, shifts in human lifestyle have led to alterations in dietary habits. The consumption of diets low in fiber and high in fat and sugar results in the production of carcinogenic metabolites during digestion. The food we consume undergoes a complex series of processes involving digesti...
Signal transducer and activator of transcription 3 (STAT3) has been an anti-cancer protein target for three decades due to its over-activation in various cancers; however, direct STAT3 inhibitors have not reached the market. In this study, a series of novel hydrazone derivatives were designed, synth...
Hodgkin lymphoma (HL) is a lymphoid malignancy derived from B cells. Globally, there were 82 409 new cases of HL in 2022, associated with 22 701 deaths. In the US, 8720 incident cases of HL and 1150 deaths due to HL were reported in 2025. Classic HL (cHL) accounts for 90% to 95% of HL cases. Cla...
In a phase 2 randomized clinical trial, high-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC). To determine if high-dose vitamin D3 added to standard chemotherapy improves ...
Mutual exclusivity (ME) and co-occurrence (CO) of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant-level patterns. We performed a comprehensive, cross-cohort analysis of BRAF, KRAS, and EGFR mutation subtype...
Dual-target c-Met/VEGFR kinase inhibitors have emerged as promising therapeutic agents for cancer therapy, although their underlying antitumor mechanisms remain poorly defined. In this study, we demonstrate that foretinib, a selective c-Met/VEGFR2 inhibitor, triggers immunogenic cell death (ICD) in ...
Metastatic colorectal cancer (mCRC) is a common and highly lethal gastrointestinal malignancy. Although chemotherapy combined with bevacizumab is a standard first-line treatment, post-treatment resistance severely limits patients' long-term survival. While the remodeling of tumor-associated macropha...
Cancer remains a leading cause of mortality worldwide, highlighting the need for therapeutic strategies that reduce systemic toxicity and drug resistance. Resveratrol (RES), a natural polyphenolic stilbenoid, possesses antioxidant, anti-inflammatory, pro-apoptotic, anti-metastatic, and chemosensitiz...
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable success in hematologic malignancies, yet demonstrates limited efficacy in solid tumors, including hepatic cancers. T-cell exhaustion and insufficient persistence represent major obstacles. We hypothesized that optimizing both m...
Cancer screening is a cornerstone of cancer control in Europe yet marked disparities persist in access, implementation, and quality assurance among national or regional programs. Building on the EU Council's 2022 recommendations and the European Union's Beating Cancer Plan, the European Consensus Pr...
Molecular underpinnings and clinical characteristics of ERBB2/HER2-mutated colorectal cancers (CRCs) remain poorly understood. We aimed to comprehensively characterize the genomic landscape and clinical features of ERBB2/HER2-mutated CRC and to compare them with those of ERBB2/HER2-amplified CRC. We...
BRAF V600E-mutant metastatic colorectal cancer (BRAF mCRC) is often associated with limited durable responses. After the publication of the randomized phase III BEACON trial investigating chemo-free regimens including BRAF inhibitors, anti-EGFR drugs, and MEK inhibitors (MEKis) in pre-treated BRAF m...
The addition of bevacizumab (BEV) to chemotherapy has shown survival benefits in metastatic colorectal cancer but may increase operative risks, potentially limiting applicability in cytoreductive surgery (CRS) for CRPM. We report the phase II BEV-IP trial investigating the feasibility, safety and po...
Immune checkpoint blockade targeting the PD-1/PD-L1 axis shows limited efficacy in microsatellite-stable (MSS) colorectal cancer (CRC), primarily due to an immunosuppressive tumor microenvironment (TME) and insufficient T-cell activation. Here, we report a peptide coacervate-mediated siRNA delivery ...
Accurate identification of actionable somatic variants is essential for therapeutic stratification in colorectal cancer (CRC). While next-generation sequencing (NGS) enables comprehensive genomic profiling, targeted approaches may provide faster and more practical alternatives for routine diagnostic...
RAS inhibitors have demonstrated limited efficacy in KRAS-mutant colorectal cancer (CRC). Here, we evaluate RMC-7977, a RAS(ON) multi-selective inhibitor, which shows a heterogeneous response in a panel of preclinical CRC models. Inhibition of PI3K signaling and cyclin D1 (CCND1) expression are stro...
Histopathological growth patterns (HGPs) have emerged as prognostic and predictive biomarkers in colorectal liver metastases (CLM). The desmoplastic/encapsulating HGP (EHGP) is associated with improved survival after surgery, whereas the replacement HGP (RHGP) is associated with poorer outcomes. How...
Colorectal cancer (CRC) remains a major cause of cancer-related mortality, particularly in advanced or metastatic disease. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway mediates cytokine-driven signaling, and its persistent activation contributes to tumor growt...
Immunotherapy for frontline mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) is effective; however, nearly half of the patients treated with single-agent PD-1 therapy will progress within 12 months. Preclinical studies in CRC and clinical dat...
KRAS mutations, present in about 40% of colorectal cancers (CRCs), are strongly associated with an immunosuppressive tumor microenvironment characterized by restricted immune infiltration and poor responses to immunotherapy. Here, we found that KRAS mutations remodel the N6-methyladenosine (m6A) epi...
Background: Enhancing the binding affinity of monoclonal antibodies (mAbs) has the potential to improve their therapeutic efficacy. In this study, we generated a novel mAb, PB-223, through affinity maturation of the parental antibody NEO-102. NEO-102 (Ensituximab) is a chimeric human IgG1 mAb that t...
Metastatic colorectal cancer (mCRC) that progresses after standard first- and second-line therapies carries a poor prognosis, and multiple third-line treatment options are available without a clearly established optimal strategy. This study aimed to comprehensively compare the efficacy and safety of...
Colorectal cancer liver metastasis (CRLM) represents the leading cause of mortality in colorectal cancer (CRC). However, the molecular mechanisms enabling metastatic adaptation within the hepatic microenvironment remain unclear. We integrated single-cell RNA sequencing, spatial transcriptomics, and...
Cetuximab and panitumumab are anti-EGFR monoclonal antibodies widely used for the treatment of colorectal cancers. However, due to various mechanisms of resistance to these targeted therapies, the patients' responses vary. These resistances remain a major obstacle in treatment and overcoming them ha...
Colorectal cancer (CRC) exhibits a highly heterogeneous tumor immune microenvironment (TME), ranging from "immune-inflamed" to "immune-desert" or "immune-excluded" phenotypes. Understanding how immune cell composition, cytolytic activity (CYT) and genomic alternations shape tumor-immune interactions...
Early-onset colorectal cancer is increasing, making reproductive health an increasingly relevant survivorship issue. While immune checkpoint inhibitors have altered the management of deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) colorectal cancer, their implications for repr...
The laminin α3 chain, encoded by LAMA3, constitutes a principal component of laminin-332 (LN-332), an essential extracellular matrix (ECM) glycoprotein governing cell adhesion, proliferation, and tissue homeostasis. This systematic review consolidates current evidence on the molecular features and ...
Objective: To investigate the incidence of immune-related adverse events (irAEs) and corresponding perioperative outcomes among patients with colorectal cancer who received neoadjuvant immunotherapy and underwent curative radical resection. Methods: This was a retrospective, multicenter, real-world ...
The 27th annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Calgary, Alberta, on 26-27 September 2025. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta,...
HER2-targeted therapy is increasingly used in colorectal cancer (CRC). However, discrepancies between conventional detection methods (immunohistochemistry [IHC]/fluorescence in situ hybridization [FISH]) and next-generation sequencing (NGS) remain to be elucidated. Furthermore, the impact of spatial...
Colorectal cancer ranks among the most common malignancies worldwide. Rectal serrated lesions represent a significant precancerous condition, accounting for approximately 30% of sporadic colorectal carcinomas. Their flat morphology and indistinct borders often lead to missed detection during routine...
Colorectal cancer (CRC) remains a major global health challenge and a leading cause of cancer-related mortality worldwide. Central to its pathogenesis is the dysregulation of interconnected signal transduction networks that govern cellular proliferation, survival, differentiation, apoptosis, and imm...